FDA officials review best practices for validating digitally derived endpoints

FDA officials emphasized the need for sponsors to validate digitally derived endpoints in the intended patient population and to pre-specify missing data strategies at every data level for clinical trials using digital health technologies. Key issues include lack of population-specific algorithm validation and incomplete missing-data handling plans, which can bias trial endpoints and affect regulatory review.

This Wire brief sits within Fusion42's coverage of Digital Health.